Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Summer Street, Suite 2300 BOSTON MA 02110 |
Tel: | 1-617-6218395 |
Website: | https://www.ironwoodpharma.com |
IR: | See website |
Key People | ||
Thomas A. Mccourt Chief Executive Officer, Director | Sravan K. Emany Chief Financial Officer, Senior Vice President | John Minardo Senior Vice President, Chief Legal Officer, Secretary |
Andrew Davis Senior Vice President, Chief Business Officer | Michael Shetzline Senior Vice President, Chief Medical Officer, Head of Research and Drug Development |
Business Overview |
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver. |
Financial Overview |
For the fiscal year ended 31 December 2023, Ironwood Pharmaceuticals, Inc. revenues increased 8% to $442.7M. Net loss totaled $1B vs. income of $175.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Research and development increase from $39.3M to $98.6M (expense), Selling, general and administrative increase of 25% to $117.1M (expense). |
Employees: | 267 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,803M as of Dec 31, 2023 |
Annual revenue (TTM): | $442.74M as of Dec 31, 2023 |
EBITDA (TTM): | $169.91M as of Dec 31, 2023 |
Net annual income (TTM): | -$1,002M as of Dec 31, 2023 |
Free cash flow (TTM): | -$842.89M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $605.72M as of Dec 31, 2023 |
Shares outstanding: | 156,528,648 as of Jan 31, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |